CVL218 for COVID-19

CVL218 may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed CVL218 in detail.
Lokugamage et al., Effects of the cross-talk between PARP12/PARP13 and nonsense mediated RNA decay pathway on RNA stability and replication of SARS-CoV-2, Frontiers in Virology, doi:10.3389/fviro.2025.1691166
Background Nonsense-mediated mRNA decay (NMD) pathway recognizes the mRNAs of host and cytoplasmic pathogens harboring aberrant features and targets them for degradation. Poly(ADP-ribose) polymerases (PARPs) superfamily consists of 17 members, among which macrodomain and zinc finger PARPs function as regulators of RNA metabolism and transcription. In this study, we investigated whether crosstalk between NMD and PARPs regulates SARS-CoV-2 RNA stability and viral infection. Methods Transgenic mice (hACE2 tg ) expressing human angiotensin-converting enzyme 2, and human alveolar epithelial cells (Calu-3 ACE2+ , A549 ACE2+ ), in which the expression of NMD factors and PARPs was modulated by molecular approaches were used for various studies. Results We found that NMD pathway targets endogenous and exogenous aberrant transcripts in human lung epithelial cells. Upon SARS-CoV-2 infection, the expression of NMD factors, up-framshift 1 and 2 (UPF1/UPF2) was decreased while PARP12 and PARP13 were significantly increased in Calu-3 ACE2+ and A549 ACE2+ cells and lung tissues of hACE2 tg mice. Depletion of PARP12/PARP13 using target-specific (vs. scrambled) siRNAs significantly enhanced the stability of NMD targeted endogenous and exogenous aberrant transcripts and SARS-CoV-2 subgenomic S, E, M, and N mRNAs in A549 ACE2+ cells, like what was noted in siUPF1/siUPF2-transfected lung epithelial cells. Conversely, overexpression of PARP12/PARP13 enhanced the NMD-dependent degradation of aberrant transcripts and SARS-CoV-2 subgenomic and genomic RNAs. Further, overexpression of PARP12/PARP13 had a dose-dependent effect in enhancing the anti-viral NMD activity and suppression of SARS-CoV-2 replication in infected cells. Conclusion We conclude that PARP12/PARP13 synergize with NMD pathway to regulate the viral mRNA stability and replication of SARS-CoV-2.
Sharun et al., A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19, Narra J, doi:10.52225/narra.v2i3.92
The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout the world. As urgency is a necessity, most efforts have focused on identifying small molecule drugs that can be repurposed for use as anti-SARS-CoV-2 agents. Although several drug candidates have been identified using in silico method and in vitro studies, most of these drugs require the support of in vivo data before they can be considered for clinical trials. Several drugs are considered promising therapeutic agents for COVID-19. In addition to the direct-acting antiviral drugs, supportive therapies including traditional Chinese medicine, immunotherapies, immunomodulators, and nutritional therapy could contribute a major role in treating COVID-19 patients. Some of these drugs have already been included in the treatment guidelines, recommendations, and standard operating procedures. In this article, we comprehensively review the approved and potential therapeutic drugs, immune cells-based therapies, immunomodulatory agents/drugs, herbs and plant metabolites, nutritional and dietary for COVID-19.
Ge et al., A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19, bioRxiv, doi:10.1101/2020.03.11.986836
AbstractThe global spread of SARS-CoV-2 requires an urgent need to find effective therapeutics for the treatment of COVID-19. We developed a data-driven drug repositioning framework, which applies both machine learning and statistical analysis approaches to systematically integrate and mine large-scale knowledge graph, literature and transcriptome data to discover the potential drug candidates against SARS-CoV-2. The retrospective study using the past SARS-CoV and MERS-CoV data demonstrated that our machine learning based method can successfully predict effective drug candidates against a specific coronavirus. Ourin silicoscreening followed by wet-lab validation indicated that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat COVID-19. Ourin vitroassays revealed that CVL218 can exhibit effective inhibitory activity against SARS-CoV-2 replication without obvious cytopathic effect. In addition, we showed that CVL218 is able to suppress the CpG-induced IL-6 production in peripheral blood mononuclear cells, suggesting that it may also have anti-inflammatory effect that is highly relevant to the prevention immunopathology induced by SARS-CoV-2 infection. Further pharmacokinetic and toxicokinetic evaluation in rats and monkeys showed a high concentration of CVL218 in lung and observed no apparent signs of toxicity, indicating the appealing potential of this drug for the treatment of the pneumonia caused by SARS-CoV-2 infection. Moreover, molecular docking simulation suggested that CVL218 may bind to the N-terminal domain of nucleocapsid (N) protein of SARS-CoV-2, providing a possible model to explain its antiviral action. We also proposed several possible mechanisms to explain the antiviral activities of PARP1 inhibitors against SARS-CoV-2, based on the data present in this study and previous evidences reported in the literature. In summary, the PARP1 inhibitor CVL218 discovered by our data-driven drug repositioning framework can serve as a potential therapeutic agent for the treatment of COVID-19.